Beigene, Springworks testing combo for solid tumors

SpringWorks Therapeutics LLC (New York, N.Y.) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) partnered to test a combination therapy in a Phase Ib trial to treat advanced solid tumors. The trial, which is slated to start in 1Q19, will evaluate SpringWorks' PD-0325901 in combination with BeiGene's lifirafenib (BGB-283).

PD-0325901 is a MEK inhibitor and lifirafenib is a second generation BRAF inhibitor...